Neurology Central

A novel biomarker for glioma: a powerful new prognostic tool?

A recent study published in the journal EBioMedicine has demonstrated that a potential biomarker, SHOX2, may help researchers to predict the survival outcome of patients with diffuse glioma brain tumors. These findings could aid the development of new therapeutic targets and allow clinicians to determine more effectively the best treatment plan for individual patients.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.